GSE189035 inositol 2 v 7 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE189035_inositol_2_v_7_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE189035_inositol_2_v_7_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE189035_inositol_2_v_7_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE189035_inositol_2_v_7_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

family with sequence similarity 30 member A

Gene

P2Y receptor family member 8

Gene

neutrophil cytosolic factor 1C (pseudogene)

Gene

USP2 antisense RNA 1

Gene

SCO-spondin, pseudogene

Gene

MIR9-3 host gene

Gene

MAP3K4 antisense RNA 1

Gene

ankyrin repeat domain 36B pseudogene 2

Gene

glutamine insufficiency regulator of glutaminase lncRNA

Gene

lncRNA induced by TGF-beta and antagonizes TGF-beta signaling 1

  • Gene

    family with sequence similarity 30 member A


  • Gene

    P2Y receptor family member 8


  • Gene

    neutrophil cytosolic factor 1C (pseudogene)


  • Gene

    USP2 antisense RNA 1


  • Gene

    SCO-spondin, pseudogene



  • Gene

    MAP3K4 antisense RNA 1


  • Gene

    ankyrin repeat domain 36B pseudogene 2


  • Gene

    glutamine insufficiency regulator of glutaminase lncRNA


  • Gene

    lncRNA induced by TGF-beta and antagonizes TGF-beta signaling 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.